Market Overview

Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest ROE

Related AKRX
16 Stocks 2 Experts Are Watching This Week
UPDATE: CRT Capital Upgrades Akorn
Merck Sells Japan Eye-Treatment Rights (Fox Business)
Related SLXP
Benzinga's M&A Chatter for Thursday December 18, 2014
Credit Suisse Raises Salix Pharmaceuticals Price Target
Making Money With Charles Payne: 10/17/14 (Fox Business)

Below are the top drugs-generic stocks on the NASDAQ in terms of return on equity.

The trailing-twelve-month return on equity at Akorn (NASDAQ: AKRX) is 18.99%. Akorn's revenue for the same period is $227.26 million.

The trailing-twelve-month return on equity at Hi Tech Pharmacal Co (NASDAQ: HITK) is 18.38%. Hi Tech Pharmacal's operating margin for the same period is 24.58%.

The trailing-twelve-month return on equity at Salix Pharmaceuticals (NASDAQ: SLXP) is 15.84%. Salix Pharmaceuticals had $775.90 million in total cash for the latest quarter.

The trailing-twelve-month return on equity at Mylan (NASDAQ: MYL) is 14.65%. Mylan's PEG ratio is 0.72.

Posted-In: Drugs-Generic Industry highest ROE NASDAQTrading Ideas

 

Related Articles (AKRX + HITK)

Around the Web, We're Loving...

Get Benzinga's Newsletters